Zanolimumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Zanolimumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetCD4
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Molar mass147 kg/mol
 ☒NcheckY (what is this?)  (verify)

Zanolimumab (expected trade name HuMax-CD4[1]) is a human monoclonal antibody and an immunosuppressive drug.[2] It was developed with the goal of treatment of rheumatoid arthritis, psoriasis, melanoma,[3] cutaneous and peripheral T-cell lymphoma.[4][5] Development of the drug was ultimately discontinued with termination of all trials.[6]

References[edit]

  1. ^ Genmab initiates Phase II Study with HuMax-CD4 Archived May 16, 2008, at the Wayback Machine
  2. ^ Mestel DS, Beyer M, Möbs M, Steinhoff M, Sterry W, Assaf C (December 2008). "Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome". Expert Opinion on Biological Therapy. 8 (12): 1929–39. doi:10.1517/14712590802528696. PMID 18990079. S2CID 58115371.
  3. ^ "TenX BioPharma". Archived from the original on April 11, 2010. Retrieved August 20, 2010.
  4. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab, American Medical Association.
  5. ^ Clinical trial number NCT00042406 for "Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker" at ClinicalTrials.gov
  6. ^ "Status of clinical trials for Zanolimumab". Retrieved 6 November 2011.